What is the recommended dosing regimen for Mydayis (mixed amphetamine salts) in patients aged 13 years and older, including starting dose, titration increments, maximum dose, and contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mydayis Dosing Guide

For patients 13 years and older with ADHD, start Mydayis at 12.5 mg once daily upon awakening, titrate weekly by 12.5 mg increments based on response and tolerability, with a maximum dose of 25 mg/day for adolescents (13-17 years) and 50 mg/day for adults. 1

Starting Dose and Administration

  • Initial dose: 12.5 mg once daily for both adults and adolescents (13-17 years) 1
  • Administer upon awakening because effects last up to 16 hours and can cause insomnia if taken later 1
  • Take consistently either with or without food (choose one approach and maintain it) 1
  • Do not substitute Mydayis for other amphetamine products on a milligram-per-milligram basis due to different amphetamine base compositions and pharmacokinetic profiles 1

Titration Schedule

Increase by 12.5 mg weekly if symptom control is inadequate and the medication is well-tolerated 1. This aligns with general amphetamine titration principles of increasing by 2.5-5 mg for immediate-release formulations 2, scaled appropriately for this extended-release product.

Monitor response using:

  • ADHD rating scales from parents and teachers (for adolescents)
  • Self-ratings and functional assessments (for adults)
  • Target symptom improvement at school, work, and home 2

Maximum Doses

  • Adolescents (13-17 years): 25 mg/day 1
  • Adults (18+ years): 50 mg/day 1

Dose Adjustments for Renal Impairment

  • Severe renal impairment (adults): Maximum 25 mg/day 1
  • Severe renal impairment (adolescents): Maximum 12.5 mg/day 1
  • End-stage renal disease (ESRD): Not recommended for any age group 1

Pre-Treatment Assessment

Before initiating Mydayis, assess for:

  • Cardiac disease: Obtain history of structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease 1
  • Baseline vital signs: Blood pressure, pulse, height, and weight 2
  • Substance use history: Screen adolescents and adults for active substance use; if present, refer to subspecialist before starting stimulants 3
  • Psychiatric conditions: Screen for risk factors for mania, active psychosis, or severe anxiety 1
  • Family history: Assess for tics or Tourette's syndrome 1

Absolute Contraindications

Do not prescribe Mydayis if the patient has: 2, 1

  • Known hypersensitivity to amphetamine products
  • Current or recent (within 14 days) monoamine oxidase inhibitor use
  • Symptomatic cardiovascular disease, including structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease
  • Active psychotic disorder
  • Glaucoma
  • Hyperthyroidism
  • Moderate to severe hypertension

Monitoring Schedule

Initial Titration Phase (Weeks 1-4)

  • Weekly contact (office visit or phone) to assess response and side effects 2
  • Collect ADHD rating scales from multiple informants
  • Monitor for common adverse effects: decreased appetite, insomnia, headache, abdominal pain 1

Maintenance Phase

  • Monthly visits until symptoms stabilize 2
  • Quarterly thereafter for stable patients
  • At each visit: Check blood pressure, pulse, weight 2
  • Annual height measurements for adolescents to monitor growth 3

Common Pitfalls to Avoid

  1. Underdosing: Community practice often uses lower doses than clinical trials 4. If symptoms persist at lower doses, continue titrating to maximum recommended dose before switching medications 2

  2. Inadequate trial duration: Allow at least one week at each dose level to assess response 2

  3. Ignoring diversion risk: Adolescents are at higher risk for medication diversion. Monitor prescription refill patterns and consider checking prescription drug monitoring programs 3

  4. Late-day dosing: Administering Mydayis after morning hours increases insomnia risk given its 16-hour duration of action 1

  5. Substitution errors: Mydayis has different pharmacokinetics than other amphetamine products; do not convert doses directly from other formulations 1

Special Considerations for Adolescents

  • Driving coverage: Ensure medication provides symptom control during driving hours, as adolescents with ADHD have increased crash risk 3
  • School performance: Mydayis's extended duration (up to 16 hours) provides coverage through after-school homework periods 1
  • Growth monitoring: Track height and weight at each visit; consider drug holidays if growth suppression occurs 3

Related Questions

What is the maximum recommended single dose of Adderall XR (mixed amphetamine salts)?
What are the indications, dosing regimen, contraindications, and monitoring recommendations for Jornay PM (mixed‑amphetamine) when used to treat ADHD?
How should I manage a patient whose Adderall XR (mixed amphetamine salts) 30 mg dose wears off after 6–7 hours?
A patient who has been off Adderall (mixed amphetamine salts) 30 mg extended‑release for 3–4 weeks—should the medication be restarted at the same dose or at a lower dose?
How should the dose of Adderall XR (mixed amphetamine salts) 10 mg be adjusted when it does not provide full daytime coverage, and when and how should a short‑acting (immediate‑release) amphetamine be added?
What are the appropriate indications, dosing schedule, contraindications, dietary restrictions, and monitoring recommendations for phenelzine (monoamine oxidase inhibitor) in patients with major depressive disorder?
Is severe leathery-type eczema common in patients undergoing chronic hemodialysis?
What is the appropriate transdermal estradiol dose for a woman with a history of migraine?
In a young adult, are mildly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels clinically concerning?
Should I wear my prescription glasses for all near‑work activities, including phone and laptop use, to prevent further vision deterioration, and what lifestyle modifications can help reverse my myopia progression?
In a patient with an isolated 2+ blood result on a urine dipstick and no urinary symptoms, should antibiotics be initiated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.